Mark P. Wentland
Professor, Department of Chemistry and Chemical Biology
Cogswell Laboratory 332
110 8th Street
Rensselaer Polytechnic Institute, Troy, NY 12180-3590
518-276-2234
Research Interests and Abbreviated Biosketch
Publications (PubMed Database)
Recently issued United States Patents
"In the News" - Press releases, webcasts and news articles pertaining to the licensing activites of our research group. Two prominent members of an opioid library that Rensselaer has licensed to Alkermes, Inc. are currently in multiple clinical trials sponsored by Alkermes. ALKS 33 is in Phase 2 clinical developement for the treatment of alcohol dependence and, in combination with buprenorphine (ALKS 5461), is being evaluated for treatment of Major Depressive Disorder (MDD) and cocaine addiction. ALKS 37 was also designed and synthesized at Rensselaer - it is currently in Phase 2b clinical trials for the treatment of Opioid-Induced Constipation (OIC).
Alkermes Pipeline
Positive results for ALKS 5461 in MDD (1/4/12)
Phase 1 results of ALKS 5461 for cocaine addiction (10/25/10)
Initiation of Phase 2b studies of ALKS 37 for OIC (10/3/11)
CHEM-4330/4340/6330 - Drug Discovery and Drug Discovery Laboratory Home Page
CHEM-4300/6300 - Medicinal Chemistry Home Page
Luke and Lily Photo Album
Professor, Department of Chemistry and Chemical Biology
Cogswell Laboratory 332
110 8th Street
Rensselaer Polytechnic Institute, Troy, NY 12180-3590
518-276-2234
Research Interests and Abbreviated Biosketch
Publications (PubMed Database)
Recently issued United States Patents
"In the News" - Press releases, webcasts and news articles pertaining to the licensing activites of our research group. Two prominent members of an opioid library that Rensselaer has licensed to Alkermes, Inc. are currently in multiple clinical trials sponsored by Alkermes. ALKS 33 is in Phase 2 clinical developement for the treatment of alcohol dependence and, in combination with buprenorphine (ALKS 5461), is being evaluated for treatment of Major Depressive Disorder (MDD) and cocaine addiction. ALKS 37 was also designed and synthesized at Rensselaer - it is currently in Phase 2b clinical trials for the treatment of Opioid-Induced Constipation (OIC).
Alkermes Pipeline
Positive results for ALKS 5461 in MDD (1/4/12)
Phase 1 results of ALKS 5461 for cocaine addiction (10/25/10)
Initiation of Phase 2b studies of ALKS 37 for OIC (10/3/11)
CHEM-4330/4340/6330 - Drug Discovery and Drug Discovery Laboratory Home Page
CHEM-4300/6300 - Medicinal Chemistry Home Page
Luke and Lily Photo Album